NCT05683886
A Study of KC1036 in Patients with Advanced Thymic Tumors
StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor Site contacts updated at 2 of 2 sitesv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Feb 2023 to Feb 22, 2023
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Objective Response Rate (ORR)
Timeframe: approximately 2 year
Secondary (4)
Progression-free survival (PFS)
Disease Control Rate (DCR)
Duration of Response (DOR)
Adverse events (AEs)
Arms and interventions
KC1036Experimental
60mg QD
Drugs: KC1036
Sites
2 sites in 1 country